Small Stocks, Big Money™

VSee Health (Nasdaq: VSEE) and The TeleDentists have introduced the first virtual oral health compliance services on the PointClickCare Marketplace. This pioneering integration provides 24/7/365 access to licensed dentists, enabling long-term care facilities to meet CMS oral health care requirements while improving outcomes for senior residents. The solution addresses key challenges in senior dental care, such as mobility issues and understaffing, by offering on-demand teledentistry services that reduce transportation risks, streamline documentation, and improve care coordination.

Alliance Entertainment (Nasdaq: AENT), through its DS division, has secured an exclusive partnership with global film and TV studio FIFTH SEASON to distribute its acclaimed content in the U.S. and Canada. This collaboration will kick off with the release of Severance Season 1 on Blu-ray and DVD on December 17, 2024, coinciding with the holiday season and anticipation for Season 2. Upcoming 2025 releases include Nine Perfect Strangers, featuring an A-list cast led by Nicole Kidman, and Truth Be Told, starring Oscar® Winner Octavia Spencer. Alliance will oversee sales and packaging localization, further cementing its leadership in physical media distribution.

Gorilla Technology Group (Nasdaq: GRRR) opened a new office in Seattle, marking a key step in its U.S. expansion and commitment to advancing smart city solutions. The new location will serve as a hub for closer collaboration with U.S. partners and clients. The move coincides with Gorilla's extended partnership with Intel® through the Intel Partner Alliance, bolstering its ability to deliver scalable AI technologies. With expertise in security, IoT, and AI-driven technologies like intelligent surveillance and advanced cybersecurity, Gorilla aims to enhance urban efficiency and safety, solidifying its role as a leader in global smart city innovation.

Calidi Biotherapeutics (NYSE American: CLDI) presented compelling new data at the International Oncolytic Virotherapy Conference (IOVC) and the Society for Immunotherapy of Cancer (SITC) Annual Meeting demonstrating the potential of its RTNova™ systemic enveloped virotherapy platform to target metastatic lung cancer and other advanced cancers. The findings highlight RTNova’s ability to transform tumor microenvironments, kill cancer cells, and deliver therapeutic payloads directly into tumors. Designed as both a monotherapy and a viral vector, the platform has potential applications across a wide range of oncology indications.